Wednesday, March 27
9:00-10:00 am

Rayburn House Office Building, Room 2043
45 Independence Avenue SW
Washington, DC 20515

Breakfast will be served at this widely-attended event. The briefing will be followed by a Q&A with the panelists.
A panel of experts and patient advocates will discuss financial and structural barriers to cancer research and treatment, emphasizing the importance of equitable access to emerging therapies for all patients. The briefing will focus on cancer-related legislative priorities and breakthroughs in the rapidly advancing field of CAR T-cell immunotherapy.
Patient Spotlight: Dimas
Dimas is a three-time survivor of non-Hodgkin lymphoma. When he received his third diagnosis—after numerous rounds of chemotherapy, a stem cell transplant, and a bone marrow transplant—he was given a prognosis of less than a year. 

Seemingly out of options, Dimas was sent to AACI member, Moffitt Cancer Center, where he met Dr. Frederick L. Locke. Dimas was enrolled in a clinical trial involving a revolutionary treatment called CAR T therapy, which uses the patient's own immune system to destroy cancerous cells. In a remarkable turnaround, the treatment worked. Learn more about Dimas and Dr. Locke.
About the Moderator
Roy A. Jensen, MD , is director of The University of Kansas Cancer Center; William R. Jewell, M.D. Distinguished Kansas Masonic Professor; the director of the Kansas Masonic Research Institute; professor of pathology and laboratory medicine; and professor of anatomy and cell biology at the University of Kansas Medical Center.
Dr. Jensen graduated from Vanderbilt University School of Medicine, where he completed his residency in anatomic pathology and a surgical pathology fellowship. His research focuses on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and on the characterization of premalignant breast disease. A member of AACI's board of directors since 2013, Dr. Jensen was named president in 2018.
About the Panelists
Ross A. Frommer, JD, is vice president for government and community affairs and associate dean at Columbia University Irving Medical Center. He represents the center on legislative and executive branch matters at the federal, state, and local levels, and assists with the development and implementation of programs in the surrounding communities. He is also a lecturer at the Columbia University School of Nursing. Ross has extensive experience working for a variety of congressional offices including as state director for the late Senator Daniel Patrick Moynihan (D-NY). Ross graduated from Tufts University and has a juris doctor degree from Georgetown University Law Center.
Kunle Odunsi, MD, PhD, FRCOG, FACOG, is deputy director, chair of the department of gynecologic oncology, executive director of the Center for Immunotherapy, and co-leader of the Tumor Immunology and Immunotherapy Research Program at Roswell Park Comprehensive Cancer Center, where he monitors all research-related initiatives, steering the development of programs and policies designed to transfer scientific discoveries to clinical settings. Dr. Odunsi has a medical degree from the University of Ife, Ile-Ife, Nigeria, received postgraduate training at the University of Cambridge, and earned his PhD at the University of Oxford, UK.
S. Elizabeth "Sam" Sharf, RN, BSN, NE-BC, CHTC, is the clinical director of the Bone Marrow Transplant and Cellular Therapy Program at the University of North Carolina, Chapel Hill. Sam oversees administration of the program which offers adult and pediatric stem cell transplants. Additionally, she oversees the largest academic adoptive cellular therapy program in the Southeast, which provides both commercial CAR T and novel Phase I/II clinical trials through UNC’s Lineberger Comprehensive Cancer Center. 
Medical Arts Building
3708 Fifth Avenue, Suite 503
Pittsburgh, PA 15213